Roivant Sciences is focusing on the discovery, development and commercialization of transformative medicines. To accelerate the commercialization of medicines, Roivant builds nimble subsidiaries they call “Vants” to develop novel technologies. Since inception, Roivant’s Vants have conducted 10 positive Phase 3 clinical trials and launched VTAMA®, a topical cream for the treatment of plaque psoriasis in adults. However, Roivant is advancing a broad and differentiated pipeline of investigational drugs across numerous therapeutic areas including immunology, oncology, hematology and dermatology.

Roivant Sciences

Founded: 2014
Location: New York, NY
Employee range: 200 - 500
Clinical stage: COM
Therapy area: Psoriasis
Drug types: NEU, END, GEN, ONC, DRM, IMM, INF, RAR, HEM, OPH, MUS, GI
Lead product: Vtama
Funding: $200M stock Feb 2023; $200M Nov 2018

Drug notes:

About:

Jobs: